Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 559 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: cetuximab Clear all
Terminated Phase 1 Interventional

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05395052
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions
FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 25, 2026, 2:41 AM EDT
Recruiting Phase 1 Interventional

TLN-372 in Advanced KRAS Mutant Solid Tumors

NCT07204340
View directory record Official record
Conditions
KRAS Mutant Solid Tumors
Interventions
TLN-372, TLN-372 in combination with cetuximab, TLN-372 in combination with pembrolizumab
Drug
Lead sponsor
Treeline Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

NCT06806852
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
BI 770371, Pembrolizumab, Cetuximab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • Minneapolis, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Terminated Phase 1 Interventional

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

NCT01552434
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

NCT00551421
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
pertuzumab, cetuximab, irinotecan hydrochloride, immunohistochemistry staining method, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT01716416
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Pazopanib, Cetuximab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

NCT00083720
View directory record Official record
Conditions
Colorectal Neoplasms, Metastases, Neoplasm
Interventions
cetuximab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
23
States / cities
Campbell, California • Los Angeles, California • Soquel, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 25, 2026, 2:41 AM EDT
Terminated Phase 1 Interventional

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

NCT03783403
View directory record Official record
Conditions
Neoplasms
Interventions
CC-95251, Rituximab, Cetuximab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

CIML NK Cell in Head & Neck Cancer

NCT04290546
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

NCT00986674
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cixutumumab, carboplatin, paclitaxel, cetuximab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
249
States / cities
Stanford, California • Aurora, Colorado • Boulder, Colorado + 171 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

NCT01420874
View directory record Official record
Conditions
Colorectal Cancer, Cancer of Pancreas, Pancreatic Neoplasm, Malignant Neoplasm of Large Intestine, Malignant Tumor of Colon, Colon Carcinoma, Cancer of Colon, Pancreatic Cancer
Interventions
FOLFOX6, EGFRBi armed ATC Infusions
Drug · Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 25, 2026, 2:41 AM EDT
Active, not recruiting Phase 1 Interventional

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

NCT05722327
View directory record Official record
Conditions
Colon Cancer, Colorectal Cancer
Interventions
MRTX849, Irinotecan, Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

NCT00477880
View directory record Official record
Conditions
Gastric Cancer, Precancerous Condition
Interventions
Cetuximab
Biological
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 25, 2026, 2:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

NCT06412198
View directory record Official record
Conditions
Metastatic Colorectal Cancer, KRAS G12C Mutations
Interventions
Cetuximab, Cemiplimab, Adagrasib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

NCT05668585
View directory record Official record
Conditions
Solid Tumors, Melanoma, NSCLC, CRC, ATC
Interventions
CFT1946, Trametinib, Cetuximab
Drug
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Sarasota, Florida • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 3 Interventional

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00003809
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
73
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Active, not recruiting Phase 2 Interventional

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

NCT02270814
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck
Interventions
nab-paclitaxel, Cisplatin, Carboplatin, Cetuximab
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
5
States / cities
Little Rock, Arkansas • Jackson, Mississippi • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 2 Interventional

Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer

NCT00315185
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetuximab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Drexel Hill, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

NCT01696955
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Interventions
Cetuximab, Laboratory Biomarker Analysis, Tivantinib
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 25, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional Results available

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

NCT01133678
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Everolimus, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 25, 2026, 2:41 AM EDT
Completed No phase listed Observational

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

NCT01416688
View directory record Official record
Conditions
Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Interventions
assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
113
States / cities
Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 25, 2026, 2:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer

NCT00226941
View directory record Official record
Conditions
Rectal Cancer, Colo-rectal Cancer
Interventions
Cetuximab, Oxaliplatin, Capecitabine, Radiotherapy, Diphenhydramine hydrochloride (HCl)
Drug · Radiation
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

NCT01935921
View directory record Official record
Conditions
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Cetuximab, Intensity-Modulated Radiation Therapy, Ipilimumab, Laboratory Biomarker Analysis
Biological · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 25, 2026, 2:41 AM EDT
Not yet recruiting Phase 1 Interventional

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

NCT06067776
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Cetuximab, Osimertinib, Tucatinib
Biological · Drug
Lead sponsor
Jonathan Riess
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 25, 2026, 2:41 AM EDT